Drug intelligence / Profile preview

carminomycin

Development stage
Unknown
Lead developer
Actinomadura carminata
Modality
Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Administration
Intravenous
01

Overview

Carminomycin is a toxic anthracycline antibiotic produced by the bacterium Actinomadura carminata. It acts as an antineoplastic agent with potent activity against various cancers, including metastatic breast cancer and acute myeloid leukemia. Carminomycin exerts its effects primarily by intercalating into DNA and inhibiting DNA topoisomerase II, which blocks DNA replication and repair, as well as RNA and protein synthesis, ultimately inducing apoptosis in tumor cells. The drug has also demonstrated antimicrobial properties against bacteria, viruses, and fungi. Its main toxicities include myelosuppression, gastrointestinal intolerance, alopecia (hair thinning), phlebitis, and in some cases cardiotoxicity[1][2][4][6].

Brand names
KarminomitsinKarminomycinAntibiotic R 588A
Other names
carubicin
02

Targets

TOP2A (DNA topoisomerase II)DNA

Beyond the preview

Go deeper on carminomycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on carminomycin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call